Overview

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Taxane-induced peripheral neuropathy (TIPN) caused by albumin-bound paclitaxel is a dose-limiting toxicity. The main symptoms of discomfort are numbness, tingling, and burning sensations in the glove-sock-like distribution of the limbs. At present, there are few effective methods for clinical treatment of TIPN, and there is no widely agreed consensus on effective treatment in the world. Therefore, it is of great clinical significance and practical value to carry out clinical research to explore drugs to relieve TIPN.
Phase:
Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital